Get the Stockscreener App
0.4076
3.53%
-0.0149
After Hours:
.42
0.0124
+3.04%
Medicus Pharma Ltd stock is traded at $0.4076, with a volume of 795.00K.
It is down -3.53% in the last 24 hours and up +27.38% over the past month.
Medicus Pharma Ltd is a clinical-stage, life sciences, biotech company focused on investing in and accelerating clinical development programs of novel and potentially disruptive therapeutic assets. The company has one operating segment.
See More
Previous Close:
$0.4225
Open:
$0.4224
24h Volume:
795.00K
Relative Volume:
0.22
Market Cap:
$23.09M
Revenue:
-
Net Income/Loss:
$-28.53M
P/E Ratio:
-0.2289
EPS:
-1.7805
Net Cash Flow:
$-20.10M
1W Performance:
-2.09%
1M Performance:
+27.38%
6M Performance:
-73.70%
1Y Performance:
-87.65%
1-Day Range:
$0.395
$0.435
1-Week Range:
$0.395
$0.4715
52-Week Range:
$0.25
$3.35
Medicus Pharma Ltd Stock (MDCX) Company Profile
Name
Medicus Pharma Ltd
Sector
Industry
Phone
610-540-7515
Address
300 CONSHOHOCKEN STATE RD., W. CONSHOHOCKEN
Compare MDCX vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MDCX
Medicus Pharma Ltd
|
0.4076 | 23.09M | 0 | -28.53M | -20.10M | -1.7805 |
LLY
Lilly Eli Co
|
1,188.58 | 1.06T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
256.98 | 618.61B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
248.08 | 438.31B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
123.54 | 305.12B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
154.05 | 293.94B | 54.66B | 13.58B | 16.05B | 7.0171 |
Medicus Pharma Ltd Stock (MDCX) Latest News
Enterprise value to revenue forward of Medicus Pharma Ltd. – BOATS:MDCXW - TradingView
Enterprise value to EBIT forward of Medicus Pharma Ltd. – BOATS:MDCXW - TradingView
Price to sales forward of Medicus Pharma Ltd. – BOATS:MDCXW - TradingView
Medicus Pharma Marks Nasdaq Anniversary With Opening Bell Ceremony - The Poughkeepsie Journal
MDCX Stock Price, Quote & Chart - ChartMill
MDCXMedicus Pharma Ltd Revenue Breakdown - Finviz
New to The Street Show #760 Airs Tonight on Bloomberg Television Across the U.S. on Independence Day Featuring Sullivan & Cromwell’s Frank Aquila, Medicus Pharma, PetVivo, FreeCast and YY Group - guardonline.com
Medicus Pharma Warrants (MDCXW) Rally 4.6% as Buyers Defend SupportCall Resistance - dars.gov.et
Is Medicus Pharma Ltd. (MDCX) Stock Gaining Momentum With Innovative Skin Cancer Treatment Technology? - Insider Monkey
Medicus Pharma Ltd Actuals & Estimates (NASDAQ:MDCX) - TradingView
MDCX Q1 2026 Earnings: Wider Than Expected Loss Reflects Pre-Revenue StageRevenue Surprise History - dars.gov.et
MDCX Forecast — Price Target — Prediction for 2027 - TradingView
Medicus Pharma on Bloomberg World - Montgomery Advertiser
Medicus Pharma Ltd (MDCXW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Medicus Pharma Ltd (MDCXW) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Medicus Pharma Ltd. (MDCX) Shows Modest Uptick Amid Consolidation at $0.46Sentiment Shift - dars.gov.et
Medicus Pharma Ltd Provides Updates on Skinject Phase 2B Pivotal Study and Teverelix Precision Medicine Program - marketscreener.com
Medicus Pharma to present SkinJect, Teverelix updates at BIO International 2026 - Proactive financial news
Medicus Pharma to Present Clinical and Regulatory Updates at 2026 Bio International Conference - Quiver Quantitative
Medicus brings SkinJect and Teverelix data to Bio 2026 - Stock Titan
Medicus Pharma to Showcase SkinJect® Registrational Strategy and Teverelix® Precision Medicine Program at Bio International 2026 - The Manila Times
Medicus Pharma Share PriceMDCX, RNS News, Articles, Quotes, & Charts (NASDAQ:MDCX) - Proactive financial news
Medicus Pharma advances Teverelix in prostate cancerICYMI - Proactive financial news
ICYMI: Medicus Seeks FDA Rare Disease Status for Skin Cancer Therapy - MyChesCo
Medicus Pharma Ltd (MDCXW) Institutional Confidence - TradingKey
Medicus Pharma Ltd (MDCXW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Medicus Pharma Ltd (MDCXW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Medicus Pharma Ltd (MDCXW) Valuation: PE, PB & Fair Value Analysis - TradingKey
Medicus Pharma Ltd (MDCXW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Medicus Pharma Ltd (MDCXW) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Medicus Pharma Ltd (MDCXW) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Medicus Pharma Ltd (MDCX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Medicus Pharma Ltd (MDCX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Medicus Pharma Ltd (MDCX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Medicus Pharma Ltd (MDCX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Medicus Pharma Ltd (MDCX) Institutional Confidence - TradingKey
Medicus Pharma Ltd (MDCX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Medicus Pharma Ltd (MDCX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Medicus Pharma Ltd (MDCX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Medicus Pharma Ltd. Announces Engagement With Reliant AI to Develop Artificial Intelligence (AI) Driven Clinical Data Analytics Platform - Montgomery Advertiser
This $9 SpaceX Stock Has Crazy Potential Geena Davis (jBXkEb6qgn) - Mshale
This $9 SpaceX Stock Has Crazy Potential Ottawa News (6IhxvTriSq) - Fathom Journal
Medicus advances Teverelix and SkinJect programs with key regulatory filings - Proactive financial news
Medicus Pharma Ltd. (MDCX) has officially submitted an application to the United States Food and Drug Administration (FDA) seeking Rare Pediatric Disease Designation for its investigational product Skinject® for the indication of Gorlin syndrome. - Bitget
Medicus advances Teverelix development with EU Phase 2b trial submission in Prostate Cancer - Proactive financial news
Small cap wrap: Medicus Pharma, First Phosphate, Standard Uranium... - Proactive financial news
Medicus Dips on FDA Nod - Baystreet.ca
Medicus Pharma seeks rare pediatric disease status for patch By Investing.com - Investing.com South Africa
Medicus Pharma seeks rare pediatric disease tag for SkinJect in Gorlin Syndrome - Proactive financial news
Medicus Pharma seeks rare pediatric disease status for patch - Investing.com
Medicus Pharma Announces U.S. Food and Drug Administration (FDA) Submission of Rare Pediatric Disease Designation Request for SkinJect® in Gorlin Syndrome - The Manila Times
Medicus Pharma Ltd Stock (MDCX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.33%
1.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):